The UAB CFAR has operated a Central Virus Core (CVC) shared resource since 1988.
The specific aims of this core are: (1) To provide specially- designed and centrally-located BSL 2-3 laboratory space to all UAB investigators so that infectious HIV research can by physically restricted to specified areas; (2) To provide and maintain the high cost equipment needed for basic HIV research within the core facility in order to facilitate and broaden the research capabilities of all investigators and to avoid redundancy in equipment purchases; (3) To provide ongoing training, supervision, and monitoring of investigators and their research staff regarding BSL 2-3 practices required for HIV research with the CVC; (4) To foster the development of HIV/AIDS research by new and established investigators by providing a CVC staff with broad experience in basic and clinical HIV research which is dedicated to these goals. The CVC consists of two centrally-located biosafety level 2-3 (BSL 2-3) laboratories and their associated professional and technical staff. These laboratories are centrally located on the UAB campus in the vicinity of the greatest concentrations of HIV researchers. Together, they constitute 2500 square feet of BSL 2-3 laboratory space including nine self-contained 100 square foot tissue culture suites. Both the individual culture suites and the outer common equipment areas are completely equipped for molecular, biological, and clinical HIV research. The core is operated under the specific usages and priority guidelines established by the Core's Advisory Committee and complies with NIH/CDC recommendations for safe operating procedures. Since funded in 1988, the research of 45 principal investigators with federally funded grants have been accommodated in these facilities. Currently, the CVC supports the research of 24 UAB faculty representing 11 different departments and divisions within the School of Medicine. The CVC has trained, supervised, and assisted 105 researchers including graduated students, postdoctoral fellows, technicians, and faculty. Currently, there are a total of 64 active CVC users. In addition to R01-type projects, the CVC has supporter the research of major NIH funded program projects and contracts awarded to UAB investigators since 1988, including NCDDG, NCVDG, PEBRA, ACTG, AVEU, NICHD and HIV Genetic Variation projects. Over 300 peer-reviewed scientific publications have results from work performed within the CVC since 1993. Funding is requested to support the basic infrastructure costs of the CVC that remain despite a substantial chargeback system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027767-11
Application #
6268006
Study Section
Project Start
1998-09-01
Project End
1999-02-28
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Nag, Mukta; De Paris, Kristina; E Fogle, Jonathan (2018) Epigenetic Modulation of CD8? T Cell Function in Lentivirus Infections: A Review. Viruses 10:
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Holdbrooks, Andrew T; Britain, Colleen M; Bellis, Susan L (2018) ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem 293:1610-1622
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Dixit, Saurabh; Sahu, Rajnish; Verma, Richa et al. (2018) Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells. Biomaterials 159:130-145
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Ladowski, Joseph M; Martens, Gregory R; Reyes, Luz M et al. (2018) Examining the Biosynthesis and Xenoantigenicity of Class II Swine Leukocyte Antigen Proteins. J Immunol 200:2957-2964
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Shi, Bi; Geng, Jianlin; Wang, Yin-Hu et al. (2018) Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4. J Immunol 200:586-594
Peng, Binghao J; Carlson, Jonathan M; Liu, Michael K P et al. (2018) Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. J Virol 92:

Showing the most recent 10 out of 955 publications